Insmed Appoints Paul Hudson, Utpal Koppikar as Independent Directors
Bitget2026/10/20 11:05- Insmed appointed Paul Hudson and Utpal Koppikar as independent directors, effective immediately.
- Hudson served as Sanofi CEO from September 2019 through February 2026, following his tenure as Novartis Pharmaceuticals CEO from 2016 to 2019.
- Koppikar has been Verily Health CFO since April 2023; previously, he served as Atara Biotherapeutics CFO from 2018 to 2023.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GM cancels long-term rare earth permanent magnet supply agreement in the US; supplier initiates arbitration
General Motors (GM.US) has canceled a long-term supply agreement with a U.S. rare earth permanent magnet manufacturer, and both parties are currently undergoing arbitration.
Tom Lee Says Yields Below 5% Mean the AI Selloff Is Nearly Over
Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) will be listed on Nasdaq tonight! IPO priced at $18 per share, aiming to raise $317.5 millions.
Lycia will issue 17.64 million shares at a price of $18 per share to raise $317.5 million.
Crypto prices
More
